Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.73 |
| ▸ | NPC1 | O15118 | 1/20 | 0.73 |
| ▸ | RAB9A | P51151 | 1/20 | 0.73 |
| ▸ | PDGFRB | P09619 | 5/20 | 0.71 |
| ▸ | PDGFRA | P16234 | 5/20 | 0.71 |
| ▸ | FLT3 | P36888 | 4/20 | 0.71 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.69 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.69 |
| ▸ | TSHR | P16473 | 1/20 | 0.69 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.60 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.60 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.60 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.60 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.60 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.60 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.60 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6389792 | 0.89 | MEN1 (0.82) | MEN1KMT2ANPC1RAB9APDGFRB | |
| SCHEMBL7066570 | 0.85 | MEN1 (0.76) | MEN1KMT2ANPC1RAB9APDGFRB | |
| SCHEMBL29402366 | 0.83 | MEN1 (0.62) | MEN1KMT2ANPC1RAB9APDGFRB | |
| SCHEMBL14739487 | 0.83 | MEN1 (0.62) | MEN1KMT2ANPC1RAB9APDGFRB | |
| SCHEMBL6865103 | 0.83 | FLT3 (1.00) | MEN1KMT2APDGFRBPDGFRAFLT3 | |
| SCHEMBL6864570 | 0.83 | FLT3 (1.00) | MEN1KMT2ANPC1RAB9APDGFRB | |
| SCHEMBL5828518 | 0.82 | MEN1 (1.00) | MEN1KMT2APDGFRBPDGFRAFLT3 | |
| SCHEMBL29354248 | 0.82 | MEN1 (1.00) | MEN1KMT2APDGFRBPDGFRAFLT3 | |
| SCHEMBL430192 | 0.82 | NPC1 (0.57) | MEN1KMT2ANPC1RAB9APDGFRB | |
| SCHEMBL10227495 | 0.81 | PDGFRB (0.68) | MEN1KMT2ANPC1RAB9APDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050267303-A1 | Cyclic indole and heteroindole derivatives and methods for making and using as pharmaceuticals | ZENTARIS AG | 2005-12-01 | — | — | US | disclosed |
| CN-1551885-A | Cyclic indole and heteroindole derivatives, the production and use thereof as medicaments | — | 2004-12-01 | — | — | CN | disclosed |
| EP-1423393-A1 | CYCLIC INDOLE AND HETEROINDOLE DERIVATIVES, THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | Zentaris GmbH (DE) | 2004-06-02 | — | — | EP | disclosed |
| US-20040039197-A1 | Cyclic indole and heteroindole derivatives and methods for making and using as pharmaceuticals | WATERWORKS, INC. | 2004-02-26 | — | — | US | disclosed |
| US-20030158216-A1 | 2-acyl indole derivatives and their use as antitumor agents | BAXTER ONCOLOGY GMBH | 2003-08-21 | — | — | US | disclosed |
| WO-2003020731-A1 | CYCLIC INDOLE AND HETEROINDOLE DERIVATIVES, THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | ZENTARIS GMBH (DE) | 2003-03-13 | — | — | WO | disclosed |
| EP-1276720-A2 | 2-ACYL INDOL DERIVATIVES AND THEIR USE AS ANTI-TUMOUR AGENTS | ASTA Medica AG (DE) | 2003-01-22 | — | — | EP | disclosed |
| US-20020091124-A1 | 2-acyl indole derivatives and their use as antitumor agents | BECKERS THOMAS (DE) | 2002-07-11 | — | — | US | disclosed |
| WO-2001082909-A2 | 2-ACYL INDOL DERIVATIVES AND THEIR USE AS ANTI-TUMOUR AGENTS | BAXTER HEALTHCARE SA (DE) | 2001-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158216-A1 | 2-acyl indole derivatives and their use as antitumor agents | IDO1, IDO2, INMT | MEN1 1405/4885KMT2A 554/4885NPC1 3131/4885 |
| US-20020091124-A1 | 2-acyl indole derivatives and their use as antitumor agents | IDO1, IDO2, INMT | MEN1 1405/4885KMT2A 554/4885NPC1 3131/4885 |
| US-20050267303-A1 | Cyclic indole and heteroindole derivatives and methods for making and using as pharmaceuticals | IDO1, IDO2, INMT | MEN1 279/4885KMT2A 4213/4885NPC1 2882/4885 |
| US-20040039197-A1 | Cyclic indole and heteroindole derivatives and methods for making and using as pharmaceuticals | IDO1, IDO2, INMT | MEN1 238/4885KMT2A 4213/4885NPC1 2258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.